Lyra Direct SARS-CoV-2 Real Time PCR Test

Highly accurate RT PCR testing for COVID-19

Accurate results in 75 minutes

Excellent performance

FDA Emergency Use Authorised

CE Marked

The Lyra Direct SARS CoV-2 assays utilise Real Time PCR that targets the conserved non-structural polyprotein (pp1ab) of the SARS CoV-2 virus for the accurate detection of the 2019 novel coronavirus that causes COVID-19. The Lyra Direct SARS-CoV-2 Assay eliminates the need for RNA purification, allowing for simple, manual sample processing before the sample is added to the Master Mix. The Lyra SARS-CoV-2 assays are focused on optimising a lab’s work flow to make these tests simple and easy to implement.

Simplifying and standardising this work flow with uniform pipetting volumes generates highly accurate results within just 75 minutes. Viral RNA is extracted from nasal, nasopharyngeal or oropharyngeal swab samples from patients with signs and symptoms of COVID-19.

The ability to mass test has been crucial in the fight against COVID-19 and RT PCR testing is a highly accurate and reliable testing method. Our verified testing options are available now to enable you to provide accurate diagnosis of coronavirus.

 

The Lyra Direct SARS CoV-2 RT PCR Test…

> Nasopharyngeal, oropharyngeal, or nasal swab samples

> Results within 75 minutes once placed in thermocycler

> FDA Emergency Use Authorised & CE Marked

> Allows for workflow flexibility to support low to high testing volumes

> Facilitates patient treatment decisions quickly

> High sensitivity and specificity

> No freezer needed; 2°C to 8°C storage

Contact us to find out more

Downloads and resources

Lyra SARS RT PCR Test Brochure
Download
Lyra SARS RT PCR Test Pack Insert
Download

Contact our team









What we do with your data

NG Biotech CARBA 5
Because there's more to public health than COVID-19...

"We love the ease and accuracy of the NG CARBA-5 lateral flow test. It has decreased our turnaround times and means we no longer need the reference laboratory to confirm our presumptive CPO results." - Holly Ciesielczuk, Senior Clinical Scientist at Barts Health NHS Trust

Read More